Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2022 | Update on huntingtin-lowering strategies under investigation for Huntington’s disease

Rajeev Kumar, MD, Rocky Mountain Movement Disorders Center, Englewood, CO, and Ann Morgan, PhD, Annexon Biosciences, discuss huntingtin-lowering strategies currently under clinical investigation in Huntington’s disease (HD). Antisense oligonucleotide (ASO), microRNA, and sRNA strategies, as well as zinc finger protein and CRISPR-Cas9 techniques, are currently being investigated, with many already being evaluated in clinical trials. The largest ASO trial in HD evaluating tominersen (GENERATION HD1) was halted after it was seen that the drug did not have any benefit, and those receiving the most frequent dosing were performing worse. Other allele-specific ASO strategies and RNA splicing modulators, such as branaplam, continue to be evaluated as HD therapies, although some trials have been put on hold due to safety concerns. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Morgan is an employee of Annexon Biosciences.
Dr Kumar is a consultant for Annexon Biosciences, and his institution receives funding from Annexon Biosciences.